Chronic Migraine Study

 

 

Chronic migraine headaches can interfere with work, family, and leisure.

Medications may not manage the pain, nausea, dizziness and other symptoms associated with migraines. This trial may help people suffering from chronic migraines maintain their lifestyle better – and it pays!

Learn more about this trial.

Clinical Trial for Cluster Headaches

cluster-headache

Cluster Headache is one of the most painful types of headaches. It’s frequently described as pain that occurs around, behind, or above the eye and along the temple in cyclic patterns or “clusters.” There are more than 200,000 cases of Cluster Headaches in the U.S. per year, and many patients describe it as a “drilling” type of sensation.

Right now, a local clinical research study is testing an investigational medication to see if it may help people who suffer from cluster headache (Investigational means the medication isn’t approved for routine clinical use).

If you qualify for this research study, you may have the opportunity to try this investigational medication. You may also receive study-related care at no cost, and compensation may be provided.

Learn more about this study here: http://curec.lk/1Uaj36v

Exelixis’ Kidney Cancer Drug Cabometyx Positive in Phase II

Exelixis, Inc. (EXELAnalyst Report) announced positive top-line data from the phase II trial, CABOSUN, on Cabometyx in patients suffering from previously untreated advanced renal cell carcinoma (RCC).

Results showed that Cabometyx led to significant improvement in progression-free survival in patients with previously untreated advanced RCC, compared with sunitinib. Consequently, the trial met its primary endpoint.

Safety data from the Cabometyx arm of the study were consistent with those observed in previous studies in patients with advanced RCC.

Final results of the trial will be presented at a medical conference shortly.

We remind investors that Cabometyx (the tablet formulation of cabozantinib) was approved by the FDA in Apr 2016 for the treatment of patients with advanced RCC, who have received prior anti-angiogenic therapy.

Meanwhile, the European Medicines Agency (EMA) has accepted a Marketing Authorisation Application (MAA) for Cabometyx for review in the same indication. Upon a potential approval, the drug would be marketed in the EU by Exelixis’ partner, Ipsen. The MAA has been granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP), which translates a review period of 150 days instead of the standard 210 days.

Exelixis also plans to submit results of the CABOSUN trial to regulatory authorities in order to discuss further development of Cabometyx and submission strategy for the treatment of first-line advanced RCC.

As per the American Cancer Society, kidney cancer is one of the top 10 most commonly diagnosed forms of cancer in both men and women in the U.S. Hence, approval of Cabometyx in first-line advanced RCC will boost its growth prospects significantly.

Exelixis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Abbott Laboratories (ABT – Analyst Report) , Johnson & Johnson (JNJ – Analyst Report) and Sanofi (SNY – Analyst Report) . All three stocks carry a Zacks Rank #2 (Buy).

From https://www.zacks.com/stock/news/218403/exelixis-kidney-cancer-drug-cabometyx-positive-in-phase-ii

Bee’s Knees, Continued

bees-knees

 

My left knee is still bothering me, even after doing Physical Therapy since January. <sigh>
It seems to get better, then something happens and it’s back to pain again.  When we were on a trip to New York a month ago, we walked a lot and climbed so many stairs, I had to buy a new brace.
Today is supposed to be my final PT but I don’t think I’m ready.
When this clinical trial came to my email, I just went through the whole survey for this but there was no doctor nearby:
 
Osteoarthritis Research Studies. Knee and hip arthritis studies enrolling now. No-cost medication. http://curec.lk/1VL5hu9
 
We’ll see what the next step is (so to speak!)
Someday…
no-pain

New Study for People with Mild to Moderate Alzheimer’s Disease

alzheimer-white

The purpose of this study is to investigate whether the study medication can help people with mild to moderate Alzheimer’s Disease improve their mental abilities such as understanding, reasoning, and judgment. The study medication will be given together with an FDA-approved Alzheimer’s medication: Aricept® (donepezil), Exelon® (rivastigmine) or Razadyne® (galantamine).

More about the study:

  • The study drug (MK-7622) is administered in the form of one capsule a day in the morning.
  • There will be 830 participants in this trial

If you are interested, please find the full study details and eligibility criteria listed here.

Eligibility Criteria:

Participants must:

  • be between 55 – 85 years old
  • be diagnosed with mild to moderate Alzheimer’s Disease (12 – 24 MMSE)
  • have a trial partner who is able to attend any study visits that require assessment
  • be currently taking a stable daily dose of acetylcholinesterase inhibitor (AChEI) such as Aricept® (donepezil), Exelon® (rivastigmine patch oral), or Razadyne® (galantamine)

Participants must not:

  • have a history of seizures or epilepsy within the last 5 years
  • have a history of mental illness
  • have been diagnosed or treated for cancer within the past 5 years (excluding basal cell, squamous cell skin cancer, in situ cervical cancer and localized prostate cancer)

Please complete the online questionnaire to check if you’re eligible for the trial.

If you’re not familiar with clinical trials, here are some FAQs:

What are clinical trials?

Clinical trials are research studies to determine whether investigational drugs or treatments are safe and effective for humans. All new investigational medications and devices must undergo several clinical trials, often involving thousands of people.

Why participate in a clinical trial?

You will have access to new investigational treatments that would be available to the general public only upon approval. You will also receive study-related medical care and attention from clinical trial staff at research facilities. Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future.

Learn why I’m talking about this Clinical Trial

FREE Patient and Survivor Conference in Northern California!

Other Stuff, Part 2: Kidney Cancer

 

 

From the Kidney Cancer Association:

 

REGISTER FOR FREE NOW!

2015 Kidney Cancer Association
Patient & Survivor Conference – Northern California

Saturday, August 15, 2015
8:00am – 3:00pm

Stanford Cancer Center

875 Blake Wilbur Drive, Palo Alto, CA 94304

Agenda has been posted. Click here to register for FREE today!

Learn about the latest treatments for kidney cancer, clinical trials and nutrition.

This conference is open to all patients, survivors, caregivers and family members. There is no cost to attend.

 Click here to register!

Click here for a list of nearby hotels. 

Please contact help@kidneycancer.org with questions or for more information.

Effects of Off-Pump and On-Pump Coronary-Artery Bypass Grafting at 1 Year

From the New England Journal of Medicine

André Lamy, M.D., P.J. Devereaux, M.D., Ph.D., Prabhakaran Dorairaj, M.D., David P. Taggart, Ph.D., Shengshou Hu, M.D., Ernesto Paolasso, M.D., Zbynek Straka, M.D., Leopoldo S. Piegas, M.D., Ahmet Ruchan Akar, M.D., Anil R. Jain, M.D., Nicolas Noiseux, M.D., Chandrasekar Padmanabhan, M.D., Juan-Carlos Bahamondes, M.D., Richard J. Novick, M.D., Prashant Vaijyanath, M.D., Sukesh Kumar Reddy, M.D., Liang Tao, M.D., Pablo A. Olavegogeascoechea, M.D., Balram Airan, M.D., Toomas-Andres Sulling, M.D., Richard P. Whitlock, M.D., Yongning Ou, M.Sc., Janice Pogue, Ph.D., Susan Chrolavicius, B.A., and Salim Yusuf, D.Phil. for the CORONARY Investigators

March 11, 2013

DOI: 10.1056/NEJMoa1301228

Coronary-artery bypass grafting (CABG) reduces mortality among patients with extensive coronary artery disease.1 CABG is usually performed with the use of cardiopulmonary bypass (on-pump CABG). With this approach, perioperative mortality is about 2%, and myocardial infarction, stroke, or renal failure requiring dialysis develop in an additional 5 to 7% of patients. The technique of performing CABG on a beating heart (off-pump CABG) was developed to reduce perioperative complications, some of which may be related to the use of cardiopulmonary bypass and to the cross-clamping of the aorta associated with the on-pump CABG procedure, and to improve long-term outcomes.

Read the entire article here

An example of a heart attack, which can occur ...

An example of a heart attack, which can occur after the use of a performance-enhancing drug. (Photo credit: Wikipedia)

.